GRI Bio, Inc. (GRI)

NASDAQ: GRI · Real-Time Price · USD

1.300

+0.035 (2.77%)

At close: Aug 13, 2025, 4:00 PM

1.310

+0.010 (0.77%)

After-hours: Aug 13, 2025, 6:18 PM EDT

GRI Bio Employees

GRI Bio had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.

Employees

4

Change (1Y)

n/a

Growth (1Y)

n/a

Revenue / Employee

n/a

Profits / Employee

-$2,819,250

Market Cap

3.25M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	4	0	-
Dec 31, 2023	4	3	300.00%
Dec 31, 2022	1	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

GRI News

13 days ago - GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
22 days ago - GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference - GlobeNewsWire
6 weeks ago - GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewsWire
6 weeks ago - GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewsWire
3 months ago - GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewsWire
3 months ago - GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - GlobeNewsWire
3 months ago - GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 - GlobeNewsWire
3 months ago - GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewsWire